Clinical Trials in Arizona

Showing 5961-5980 of 16,770 trials

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052

The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene MYC. MYC oncogene activation is important to the growth of many hematologic and solid tumor malignancies. In this study the Sponsor proposes to study DCR-MYC and its ability to inhibit MYC and thereby inhibit cancer cell growth.

Hepatocellular Carcinoma

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company21 participantsStarted Jan 2015

Scottsdale, Arizona, United States • Boston, Massachusetts, United States • San Antonio, Texas, United States +3 more locations

TERMINATEDNA42 miles

Feasibility Study on LITT for Medical Refractory Epilepsy

NCT02820740

Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.

Epilepsy

Monteris Medical4 participantsStarted Apr 2017

Phoenix, Arizona, United States • New Haven, Connecticut, United States • Kansas City, Kansas, United States +2 more locations

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

Feasibility Study on LITT for Medical Refractory Epilepsy

Find Trials by Condition in Arizona

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Vibrant Capsule vs. Placebo for Patient Suffering From Constipation

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Impact of Microvascular Inflammation on Kidney Allograft Outcome

A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

C-myc Biomarker Study for Diabetic Foot Ulcers

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia